Labeling Reagents and Methods of Their Use
US-2015355186-A1 · Dec 10, 2015 · US
Pentacyclic compound
US10239889B1 · US · B1
| Field | Value |
|---|---|
| Publication number | US-10239889-B1 |
| Application number | US-201816122116-A |
| Country | US |
| Kind code | B1 |
| Filing date | Sep 5, 2018 |
| Priority date | Sep 7, 2017 |
| Publication date | Mar 26, 2019 |
| Grant date | Mar 26, 2019 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof:
First claim
Opening claim text (preview).
What is claimed is: 1. A compound selected from the group consisting of: 3-fluoro-6,11-dimethyl-6,7,10,11,12,13-hexahydrobenzo[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-5,14-dione: 5,10-dimethyl-5,6,9,10,11,12-hexahydropyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a]thieno[2,3-f][1,4]diazepine-4,13-dione: 5,10-dimethyl-5,6,9,10,11,12-hexahydropyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a]thieno[3,2-][1,4]diazepine-4,13-dione: (3aS,14aR)-5,10-dimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione: (3aR,14aR)-5,10-dimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione: and (3aS,14aS)-5,10-dimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[ft]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione: or a pharmaceutically acceptable salt thereof. 2. 3-Fluoro-6,11-dimethyl-6,7,10,11,12,13-hexahydrobenzo[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-5,14-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 3. 5,10-Dimethyl-5,6,9,10,11,12-hexahydropyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a]thieno[2,3-f][1,4]diazepine-4,13-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 4. 5,10-Dimethyl-5,6,9,10,11,12-hexahydropyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a]thieno[3,2-f][1,4]diazepine-4,13-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 5. (3aS,14aR)-5,10-Dimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 6. (3aR,14aR)-5,10-Dimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[f]pyrido[4″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 7. (3aS,14aS)-5,10-DDimethyl-3,3a,5,6,9,10,11,12-octahydro-1H-cyclopenta[f]pyrido[4′″,3″:4′,5′]thieno[2′,3′:4,5]pyrimido[1,2-a][1,4]diazepine-4,13(2H,14aH)-dione or a pharmaceutically acceptable salt thereof according to claim 1 : 8. A pharmaceutical composition comprising the compound or pharmaceutically acceptable salt thereof according to claim 1 and one or more pharmaceutically acceptable additives. 9. A method of treating a disease selected from a group consisting of Alzheimer's disease, Dementia with Lewy bodies and Parkinson disease with dementia comprising administering the compound or pharmaceutically acceptable salt thereof according to claim 1 to a patient in need thereof. 10. The method according to claim 9 wherein the disease is Alzheimer's disease. 11. The method according to claim 9 wherein the disease is Dementia with Lewy bodies. 12. The method according to claim 9 wherein the disease is Parkinson disease with dementia.
Assignees
Inventors
Classifications
for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia · CPC title
Anti-Parkinson drugs · CPC title
- C07D495/22Primary
in which the condensed system contains four or more hetero rings · CPC title
having two nitrogen atoms, e.g. dilazep · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10239889B1 cover?
- The present invention provides compounds represented by formulas (1) to (VI) or pharmaceutically acceptable salts thereof:
- Who is the assignee on this patent?
- Eisai R&D Man Co Ltd
- What technology area does this patent fall under?
- Primary CPC classification C07D495/22. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) (B1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).